US Pharma MarketingThe post Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial appeared first on Clinical Trials Arena.
Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial
Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL. Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL. According to GlobalData, by 2030, BiTEs are forecast to generate $20.6bn in sales. Credit: Nemes Laszlo / Shutterstock.com Genmab’s Phase III trial of a combination therapy including its bispecific T-cell engager (BiTE) combination, including Epkinly, has met its primary endpoint in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In the EPCORE DLBCL-4 trial (NCT06508658), Genmab investigated a…
Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL.
Source: Clinical Trials Arena